A trial looking at either ixabepilone or paclitaxel with bevacizumab for breast cancer that has come back (CA163115)

Cancer type:

Breast cancer

Status:

Results

Phase:

Phase 2

This trial looked at either ixabepilone with bevacizumab (Avastin) or paclitaxel (Taxol) with bevacizumab for breast cancer that has come back after treatment.

More about this trial

The main treatments for breast cancer are surgeryradiotherapyhormone therapy and chemotherapy. You may have one, some, or all of these treatments and they generally work well. But unfortunately breast cancer can come back after treatment.

Doctors may treat breast cancer that has come back with chemotherapy or hormone therapyPaclitaxel is a chemotherapy drug they often use. Ixabepilone is one of a group of chemotherapy drugs known as epothilone analogues. They work in a similar way to paclitaxel.

Bevacizumab is a type of biological therapy called a monoclonal antibody. In this trial, the researchers looked at different ways of having ixabepilone and bevacizumab. They also looked at a combination of paclitaxel and bevacizumab.

The aims of the study were to

  • Find out how well the different drug combinations work for breast cancer that has come back after treatment
  • Learn more about the side effects

Summary of results

The trial team found that ixabepilone and bevacizumab could be a useful treatment for breast cancer that has come back after treatment.

This trial recruited 123 people. They were put into 1 of 3 groups at random.

  • Group A had ixabepilone 3 times in every 4 weeks, and bevacizumab once every 2 weeks
  • Group B had ixabepilone and bevacizumab once every 3 weeks
  • Group C had paclitaxel 3 times in every 4 weeks, and bevacizumab once every 2 weeks

The research team found that the cancer responded to treatment in

  • 22 out of 46 people (48%) in group A
  • 32 out of 45 people (71%) in group B
  • 20 out of 32 people (63%) in group C

When they looked at how many people were living a year after treatment, they found it was similar in all 3 groups

They also looked at the side effects. They found that more people in group B had serious side effects. The most common side effect was a drop in the number of white blood cells called neutrophils. This affected

  • 7 people in group A (16%)
  • 27 people in group B (60%)
  • 7 people in group C (22%)

So overall the research team found that having ixabepilone every 3 weeks worked best but caused more side effects. Having ixabepilone 3 times in every 4 weeks didn’t work as well, but caused fewer side effects. They concluded that ixabepilone and bevacizumab was promising as a treatment for breast cancer that has spread.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr. Mark Verrill

Supported by

Bristol-Myers Squibb
Experimental Cancer Medicine Centre (ECMC)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 894

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Harriet wanted to try new treatments

A picture of Harriet

“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page